Skip to main content

Table 2 OS in patients with KRAS G12C or wild-type tumors with high PD-L1 (≥50%) and receiving 1L CIT alone

From: Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

 

N

Death

Median OS (95% CI)

Adjusted* HR (95% CI)

p-value

KRAS wild-type

65

41

10.0 (5.2–17.5)

Reference

KRAS G12C

43

13

32.6 (19.4-NR)

0.57 (0.28–1.14)

p = 0.11

  1. *Adjusted for age, sex, de novo or recurrent disease, metastasis at baseline, TMB status and histology
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us